Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Inflammatory response

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,434 result(s) found for: Inflammatory response. Displaying page 1 of 72.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-001714-38 Sponsor Protocol Number: COVID-RESCAP Start Date*: 2021-03-04
    Sponsor Name:Red Cross Hospital Beverwijk
    Full Title: Alkaline phosphatase for reducing systemic inflammatory response syndrome (SIRS) in patients with Sars-CoV-2 infection and acute respiratory insufficiency (COVID 19)
    Medical condition: COVID 19
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004867 10062357 SIRS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016453-17 Sponsor Protocol Number: IEO S504/409 Start Date*: 2009-12-17
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Phase II study of preoperative bevacizumab plus weekly paclitaxel, carboplatin and metronomic cyclophosphamide � trastuzumab and endocrine therapy for inflammatory breast cancer
    Medical condition: Inflammatory breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021980 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018529-21 Sponsor Protocol Number: 25286464463845 Start Date*: 2010-05-12
    Sponsor Name:Karolinska Institutet, Institution CLINTEC, enheten för anestesi
    Full Title: Albuminkinetik vid generell inflammation en explorativ studie på patienter vid stor bukkirurgi
    Medical condition: General inflammation and systemic inflammatory response syndrome (SIRS) due to large abdominal surgery
    Disease: Version SOC Term Classification Code Term Level
    12.1 10021995 Inflammatory reaction LLT
    12.1 10051379 Systemic inflammatory response syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003291-35 Sponsor Protocol Number: ML 19884 Start Date*: 2007-11-26
    Sponsor Name:ROCHE
    Full Title: Phase II, open label, neoadjuvant study of Bevacizumab in patients with inflammatory or locally advanced breast cancer
    Medical condition: Patients with inflammatory or locally advanced operable breast cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10021980 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001906-29 Sponsor Protocol Number: EGF103009 Start Date*: 2005-08-18
    Sponsor Name:GlaxoSmithKline R&D Ltd
    Full Title: Phase II study to evaluate the efficacy, safety and pharmacodynamics of lapatinib in patients with relapsed or refractory inflammatory breast cancer
    Medical condition: Relapsed or refractory infammatory breast cancer (IBC)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10021974 Inflammatory breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-002968-49 Sponsor Protocol Number: BN43118 Start Date*: 2022-06-24
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN PATIENTS WITH GUILLAIN-BARRÉ S...
    Medical condition: Guillain-Barré syndrome (GBS)
    Disease: Version SOC Term Classification Code Term Level
    22.1 10029205 - Nervous system disorders 10018767 Guillain-Barre syndrome PT
    21.1 10029205 - Nervous system disorders 10018766 Guillain Barre syndrome LLT
    21.1 10029205 - Nervous system disorders 10042812 Syndrome Guillain-Barre LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001347-31 Sponsor Protocol Number: RF-2016-02361887 Start Date*: 2018-07-30
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: Anti-nerve reactivity as predictor of response to immune therapy in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): A proof of concept study with rituximab in patie...
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10072650 CIDP LLT
    21.1 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005034-36 Sponsor Protocol Number: CIDPRIT Start Date*: 2018-05-22
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: An Italian database-based randomized controlled trial with Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10072650 CIDP LLT
    21.1 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    21.1 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005414-20 Sponsor Protocol Number: 14/05 Start Date*: 2006-03-06
    Sponsor Name:ISTITUTO PER L INFANZIA BURLO GAROFOLO
    Full Title: Randomized controlled double-blind Vs. placebo multicentre study on the safety and effectiveness of thalidomide in the treatment of refractory Crohn s disease and ulcerative colitis.
    Medical condition: Inflammatory Bowel Disease Crohn Disease, Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10021972 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024454-10 Sponsor Protocol Number: 1200.89 Start Date*: 2011-07-21
    Sponsor Name:Boehringer Ingelheim
    Full Title: An open label, phase II trial of afatinib with or without vinorelbine for the treatment of HER2-overexpressing Inflammatory Breast Cancer
    Medical condition: Locally advanced or metastic Inflammatory Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10021974 Inflammatory breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001136-76 Sponsor Protocol Number: KB034Emendamenton°2 Start Date*: 2007-07-09
    Sponsor Name:KEDRION
    Full Title: Double blind Randomized Controlled trial of prolonged treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)with high dose intravenous immunoglobulins (IVIg) or intravenous m...
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-005558-31 Sponsor Protocol Number: I10E-1306 Start Date*: 2015-01-08
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: International, multicentre, efficacy and safety study of I10E in the maintenance treatment of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM study I1...
    Medical condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Completed) IT (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005557-73 Sponsor Protocol Number: I10E-1302 Start Date*: 2014-10-21
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: An international, multicentre, efficacy and safety study of I10E in initial and maintenance treatment of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy
    Medical condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003468-19 Sponsor Protocol Number: NL50040.029.14 Start Date*: 2015-01-08
    Sponsor Name:VU University Medical Center
    Full Title: The effects of hyperoxia on organ dysfunction and outcome in critically ill patients with SIRS
    Medical condition: Intensive Care patients with the systemic inflammatory response syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004867 10062357 SIRS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004503-13 Sponsor Protocol Number: KOLprednisolone Start Date*: 2012-12-12
    Sponsor Name:Bispebjerg Hospital
    Full Title: Effect of Glococorticosteroids on physical performance in patients with chronic obstructive pulmonary disease and acute inflammatory response after exercise
    Medical condition: To investigate the effects of prednisone and Solu-Medrol on physical performance in patients with chronic obstructive pulmonary disease(COPD). Furthermore to examine the inflammatory response durin...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019037-10 Sponsor Protocol Number: INITIAtE Start Date*: 2010-11-24
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
    Full Title: IcatibaNt In Treatment of Idiopathic Angio Edema.
    Medical condition: Idiopathic angioedema.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051379 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002052-24 Sponsor Protocol Number: MERCY Start Date*: 2017-12-14
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Continuous infusion versus intermittent administration of meropenem in critically ill patients. A multicenter randomized double blind trial.
    Medical condition: We are planning a large multicentre randomized controlled study to confirm the beneficial effect of continuous infusion of meropenem against bolus administration as indicated by a composite outcome...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004867 10062357 SIRS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000783-16 Sponsor Protocol Number: ML21531 Start Date*: 2008-06-18
    Sponsor Name:ROCHE SAS
    Full Title: Multicenter, phase II trial assessing the efficacy and safety of bevacizumab (Avastin®) combined to trastuzumab (Herceptin®) based chemotherapy in patients with primary inflammatory HER2+ breast ca...
    Medical condition: Primary inflammatory HER2+ breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065430 HER-2 positive breast cancer LLT
    9.1 10021974 Inflammatory breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003343-37 Sponsor Protocol Number: IEO675 Start Date*: 2019-01-23
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Combination of pembrolizumab with oral metronomic cyclophosphamide in patients with chest wall breast cancer (PERICLES): A phase II study.
    Medical condition: Locally recurrent, inoperable, and/or metastatic inflammatory breast cancer with lymphangitic spread to the chest wall
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021980 Inflammatory carcinoma of the breast PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-000369-12 Sponsor Protocol Number: MOX-420-WIE-0030-I Start Date*: 2006-05-24
    Sponsor Name:Institute of Anaesthesiology, German Heart Centre
    Full Title: An open, randomized, single-center study assessing the serum time-concentration curves and the effect of prophylactic moxifloxacin (in comparison with cefuroxime) on the early inflammatory response...
    Medical condition: In this study prophylactic moxifloxacin 400 mg i.v. is compared with the above mentioned standard antibiotic prophylaxis cefuroxime regimen with special consideration to the postoperative inflammat...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 11:34:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA